Talluto D M, Wyse T B, Krupin T
Curr Opin Ophthalmol. 1997 Apr;8(2):2-6. doi: 10.1097/00055735-199704000-00002.
Dorzolamide, a topically active carbonic anhydrase inhibitor, is an effective new glaucoma medication that creates a decrease in intraocular pressure similar to that produced by beta-blockers. When beta-blockers are contraindicated, dorzolamide may be used as a first-line therapy. It has excellent additivity with other topical ocular hypotensive medications, including beta-blockers and pilocarpine. Systemic side effects are minimal, particularly compared with those of oral carbonic anhydrase inhibitors. However, local side effects, including corneal edema in patients with borderline endothelial function, may occur. Decreased visual acuity and allergic reactions, which occur frequently, may curtail the use of dorzolamide in some patients.
多佐胺是一种局部活性碳酸酐酶抑制剂，是一种有效的新型青光眼药物，可降低眼压，其降眼压效果与β受体阻滞剂相似。当β受体阻滞剂禁忌使用时，多佐胺可作为一线治疗药物。它与其他局部降眼压药物（包括β受体阻滞剂和毛果芸香碱）具有良好的相加作用。全身副作用极小，尤其是与口服碳酸酐酶抑制剂相比。然而，可能会出现局部副作用，包括内皮功能临界患者的角膜水肿。视力下降和过敏反应较为常见，这可能会限制多佐胺在某些患者中的使用。
